A randomized, multi-center, double-blind, placebo-controlled, parallel-group, dose-ranging safety, efficacy, and tolerability study of two doses of epinastine [Inspire Pharmaceuticals] nasal spray (0.05% and 0.1%) vs. placebo in subjects with seasonal allergic rhinitis.

Trial Profile

A randomized, multi-center, double-blind, placebo-controlled, parallel-group, dose-ranging safety, efficacy, and tolerability study of two doses of epinastine [Inspire Pharmaceuticals] nasal spray (0.05% and 0.1%) vs. placebo in subjects with seasonal allergic rhinitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2014

At a glance

  • Drugs Epinastine (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Inspire Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2011 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.
    • 29 May 2007 Status change from in progress to completed according to NTC.
    • 08 May 2007 Status changed from initiated to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top